121 Global differences in SAB management 6 Table 1. Regional practice patterns for S. aureus bacteremia Total N = 2031 North America N = 701 Europe N = 573 Asia N = 409 Oceania N = 182 South America N = 124 Africa N = 42 p⁺ Cefazolin vs ASP in MSSAB <0.01 Regarded equally effective 1470 (81.4) 557 (85.2) 416 (78.8) 235 (76.5) 148 (85.5) 86 (81.1) 28 (75.7) Reasons to extend therapy from 2 weeks to 4 weeks or more <0.01 Positive BC 48-72h after start abx 1248 (84.0) 516 (89.7) 363 (83.3) 169 (76.1) 132 (86.8) 54 (65.9) 14 (77.8) Immunocompromised 873 (59.5) 411 (72.0) 187 (43.2) 134 (62.9) 94 (63.1) 36 (44.4) 11 (55.0) Unknown portal of entry 787 (54.3) 386 (68.4) 178 (41.7) 102 (48.1) 87 (58.0) 28 (36.4) 6 (31.6) Fever 72h after first positive BC 746 (51.6) 331 (58.8) 203 (47.3) 94 (45.4) 78 (52.0) 32 (41.0) 8 (40.0) Community acquisition 460 (31.3) 231 (40.7) 96 (22.1) 44 (20.4) 71 (46.4) 14 (17.9) 4 (21.1) Oral switch therapy in different infection foci1 Skin/soft tissue infection 922 (59.3) 330 (56.2) 305 (66.3) 140 (58.8) 85 (54.5) 47 (54.0) 15 (55.6) 0.01 Osteomyelitis 840 (54.0) 260 (44.3) 301 (65.4) 106 (44.5) 105 (67.3) 60 (69.0) 8 (29.6) <0.01 Spondylodiscitis 659 (42.4) 155 (26.4) 275 (59.8) 84 (35.3) 94 (60.3) 46 (52.9) 5 (18.5) <0.01 Prosthetic joint septic arthritis 610 (39.2) 144 (24.5) 260 (56.5) 75 (31.5) 89 (57.1) 37 (42.5) 5 (18.5) <0.01 Prosthetic valve endocarditis 130 (8.4) 24 (4.1) 54 (11.7) 14 (5.9) 32 (20.5) 5 (5.7) 1 (3.7) <0.01 All of the above 120 (7.7) 22 (3.7) 44 (9.6) 30 (12.6) 16 (10.3) 5 (5.7) 3 (11.1) <0.01 18F-FDG PET/CT for SAB PET/CT readily available 829 (55.6) 278 (48.9) 341 (78.0) 106 (46.7) 78 (51.3) 24 (28.6) 2 (9.1) <0.01 Covered by insurance for SAB 610 (42.2) 177 (33.2) 332 (77.4) 41 (18.2) 37 (24.3) 21 (25.0) 2 (9.1) <0.01 PET/CT use in some/all patients 1009 (67.8) 293 (51.1) 409 (93.8) 125 (57.0) 124 (82.8) 50 (61.0) 4 (12.7) <0.01 Never use PET/CT in SAB patients 479 (32.2) 281 (49.0) 27 (6.2) 96 (43.0) 26 (17.2) 32 (39.0) 17 (77.3) <0.01 Available, but never use in SAB2 101 (12.2) 63 (22.7) 5 (1.5) 24 (23.1) 8 (10.3) 1 (4.2) - <0.01 Actions following diagnosis of persistent SAB Additional diagnostic testing 1610 (95.8) 605 (97.0) 484 (96.6) 242 (92.0) 161 (97.6) 91 (96.8) 27 (79.4) <0.01 Change antibiotic management 1246 (74.7) 523 (83.5) 316 (63.8) 207 (80.2) 106 (64.6) 72 (76.7) 22 (68.8) <0.01
RkJQdWJsaXNoZXIy MTk4NDMw